A detailed history of Daiwa Securities Group Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 326 shares of MYGN stock, worth $4,469. This represents 0.0% of its overall portfolio holdings.

Number of Shares
326
Previous 326 -0.0%
Holding current value
$4,469
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$14.51 - $20.99 $856 - $1,238
59 Added 22.1%
326 $5,000
Q3 2021

Nov 05, 2021

BUY
$29.97 - $36.66 $3,776 - $4,619
126 Added 89.36%
267 $9,000
Q4 2020

Feb 04, 2021

SELL
$12.16 - $19.77 $3,392 - $5,515
-279 Reduced 66.43%
141 $3,000
Q4 2019

Jan 31, 2020

SELL
$20.93 - $35.1 $962 - $1,614
-46 Reduced 9.87%
420 $11,000
Q1 2019

Apr 26, 2019

BUY
$26.93 - $34.7 $2,235 - $2,880
83 Added 21.67%
466 $15,000
Q1 2018

May 02, 2018

BUY
$28.83 - $41.01 $11,041 - $15,706
383 New
383 $11,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.